Stockscreener 앱 받기
1.03
3.12%
0.03
전일 마감가:
$1.00
열려 있는:
$1.06
하루 거래량:
4.78M
Relative Volume:
0.71
시가총액:
$349.28M
수익:
$4.47M
순이익/손실:
$-71.67M
주가수익비율:
-4.4435
EPS:
-0.2318
순현금흐름:
$-59.58M
1주 성능:
-2.72%
1개월 성능:
-26.34%
6개월 성능:
-47.12%
1년 성능:
-32.16%
1일 변동 폭
$1.02
$1.09
1주일 범위
$0.9701
$1.09
52주 변동 폭
$0.97
$2.725
오큐젠 Stock (OCGN) Company Profile
명칭
Ocugen Inc
전화
484-328-4701
주소
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.03 | 339.11M | 4.47M | -71.67M | -59.58M | -0.2318 |
VRTX
Vertex Pharmaceuticals Inc
|
519.82 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
786.56 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
197.76 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
961.17 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
209.47 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
오큐젠 Stock (OCGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-17 | 개시 | Canaccord Genuity | Buy |
| 2026-03-11 | 개시 | Oppenheimer | Outperform |
| 2024-10-15 | 개시 | Maxim Group | Buy |
| 2023-03-01 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | 개시 | Mizuho | Buy |
| 2022-06-15 | 재개 | ROTH Capital | Buy |
| 2022-06-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-07-26 | 개시 | Noble Capital Markets | Outperform |
| 2021-06-11 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2021-05-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
모두보기
오큐젠 주식(OCGN)의 최신 뉴스
OCGN Looks 22.0% Overvalued on GF Value™ - GuruFocus
Ocugen receives provisional approval for gene therapy in Bahamas By Investing.com - Investing.com Canada
Ocugen Announces Expanded Access Program for OCU400 in Retinitis Pigmentosa Following LARTA Provisional Approval - quiverquant.com
Ocugen Stockholders Approve Meeting Adjournment for Share Increase - The Globe and Mail
Ocugen stockholders approve adjournment of special meeting for share increase vote - Investing.com Nigeria
Why Is Ocugen (NASDAQ:OCGN) Back in Focus as Wall Street Balances Growth and Defensive Demand? - Kalkine Media
Form 8K Ocugen, Inc For: 23 September By Investing.com - Investing.com Nigeria
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
H.C. Wainwright Maintains Ocugen(OCGN.US) With Buy Rating, Maintains Target Price $9.5 - Moomoo
OCGN: Proposal to increase authorized shares delayed due to insufficient votes; adjournment approved - TradingView
OCGN: Proposal to increase authorized shares stalled; adjourned meeting set for further voting - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Why Did OCGN Stock Rise Today? - Stocktwits
Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch
Ocugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline Advances - TradingView
Ocugen Inc. stock rises Monday, outperforms market - MarketWatch
Ocugen CEO Musunuri sells $589,109 in shares, priced $1.06-$1.31 By Investing.com - Investing.com Australia
Ocugen CEO Musunuri sells $589,109 in shares, priced $1.06-$1.31 - investing.com
Ocugen: Q3 Data Catalyst In Stargardt Disease Feels Critical (NASDAQ:OCGN) - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Axsome Therapeutics (AXSM) and Ocugen (OCGN) - The Globe and Mail
Ocugen to Share Ophthalmic Gene Therapy Progress - TipRanks
Ocugen Inc. stock falls Thursday, underperforms market - MarketWatch
OCGN Stock Slips As Traders Focus On Weak Financials - StocksToTrade
OCGN Stock Slips As Weak Financials Weigh On Momentum - timothysykes.com
Ocugen: My Hold Rating Continued On OCU410ST Advancement And Upcoming Catalysts (OCGN) - Seeking Alpha
What's Happening With Ocugen Stock Thursday? - TradingView
H.C. Wainwright cuts Ocugen stock price target to $9.50 on trial delay - Investing.com India
OCGN Maintains Buy by HC Wainwright & Co. -- Price Target Lowered to $9.50 - GuruFocus
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
An Ocugen (NASDAQ: OCGN) insider plans a stock sale; the exact size is detailed in an SEC notice - Stock Titan
OCGN Looks 32.9% Overvalued on GF Value™ Amid Phase 2/3 Trial Se - GuruFocus
Ocugen slips after Stargardt disease trial data (OCGN:NASDAQ) - Seeking Alpha
OCGN Stock Slides As Traders Focus On Cash Burn And Key Support - timothysykes.com
Ocugen doses first patient in phase 3 GA gene therapy trial - Glance by Eyes On Eyecare
Ocugen Announces US$40 Million Registered Direct Offering Priced at $2.00 Per Share - Minichart
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen Inc (NASDAQ: OCGN) Stock Price, News & Analysis - Kalkine
Ocugen Doses First Patient in Phase 3 Trial of OCU410 for GA - cgtlive.com
Malvern’s Ocugen Starts Pivotal Trial for Eye Gene Therapy - MyChesCo
Ocugen stock edges higher as investors watch recent quarterly figures - AD HOC NEWS
Ocugen Stock Price Forecast. Should You Buy OCGN? - StockInvest.us
Ocugen (NASDAQ:OCGN) Penny Stock Nears Major Gene Therapy Catalyst - Kalkine Media
OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy - Yahoo Finance
Ocugen Doses First Patient in Global Phase 3 Trial of OCU410 for Geographic Atrophy - Eyewire+
Ocugen Eases on Tests - Baystreet.ca
Ocugen doses first patient in phase 3 gene therapy trial for GA - Investing.com Canada
OCGN Looks 61.0% Overvalued on GF Value™ - GuruFocus
Ocugen Doses First Patient in Global Phase 3 ArMaDa3 Trial of OCU410 for Geographic Atrophy and Receives FDA RMAT Designation - Quiver Quantitative
Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - Ocugen, Inc.
Ocugen Announces First Patient Dosed in Phase 3 - GlobeNewswire
Malvern Biotech Ocugen to Present New Eye Gene Therapy Data - MyChesCo
오큐젠 (OCGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
오큐젠 주식 (OCGN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Musunuri Shankar | Chief Executive Officer |
Sep 09 '26 |
Sale |
1.12 |
57,264 |
64,136 |
1,088,035 |
4.12%
1.10%
자본화:
|
볼륨(24시간):